Pharmaceutical

Eisai and Biogen launch LEQEMBI for Alzheimer’s in China

Eisai and Biogen have announced the introduction of LEQEMBI (lecanemab) for the treatment of Alzheimer's disease (AD) in China.

Jun 30, 2024 - 04:00
Eisai and Biogen launch LEQEMBI for Alzheimer’s in China
Eisai and Biogen have announced the introduction of LEQEMBI (lecanemab) for the treatment of Alzheimer's disease (AD) in China.
Read the original article

Tags:

Previous Article

Holoclara gains Series A financing for worm-derived therapies

Next Article

AI Firm Formation Bags $372 Series D Funding

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pharmalittle: Many employer health plans won’t pay for obesity drugs; FDA panel rejects Intercept NASH drug

STAT+: Pharmalittle: Many employer health plans won’t p...

May 23, 2023

Upstream Bio raises funds to advance clinical development of UPB-101

Upstream Bio raises funds to advance clinical developme...

Jun 9, 2023

FDA agrees wider use of BioMarin’s BRINEURA for CLN2

FDA agrees wider use of BioMarin’s BRINEURA for CLN2

Jul 26, 2024